Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON FORTE versus INAPSINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON FORTE versus INAPSINE.
ETRAFON-FORTE vs INAPSINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON-FORTE is a combination of perphenazine (a phenothiazine antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks postsynaptic dopamine D2 receptors in the mesolimbic system. Amitriptyline inhibits reuptake of serotonin and norepinephrine, enhancing neurotransmission. Additionally, amitriptyline blocks histamine H1, muscarinic, and alpha-adrenergic receptors.
Butyrophenone antipsychotic; antagonizes dopamine D2 receptors in the CNS, also exhibits alpha-adrenergic blocking activity.
ETRAFON-FORTE (perphenazine 4 mg / amitriptyline 25 mg) oral tablets: 1 tablet three times daily or 1 tablet four times daily. Maximum daily dose: 4 tablets (perphenazine 16 mg / amitriptyline 100 mg).
IM: 2.5-10 mg every 3-4 hours as needed; IV: 2.5-10 mg slow IV push (over 2-3 minutes), repeat every 30-60 minutes as needed; maximum total dose 20 mg.
None Documented
None Documented
Terminal elimination half-life of perphenazine: 8-12 hours; amitriptyline: 13-36 hours (mean ~20 hours). Steady-state achieved in 3-7 days. Clinical context: twice-daily dosing maintains therapeutic levels.
Terminal elimination half-life is 10-22 hours (mean 14.5 hours) in adults; may be prolonged in elderly or patients with hepatic impairment.
Primarily renal (approximately 70-80% as metabolites, <5% unchanged). Biliary/fecal elimination accounts for about 15-20% due to enterohepatic recirculation of metabolites.
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal excretion accounts for approximately 20-30%.
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic